Report Detail

Request for Sample of this report

Pharma & Healthcare COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2026

  • RnM4062804
    • |
  • 16 June, 2020
    • |
  • Global
    • |
  • 113 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Postmenopausal Vaginal Atrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
Premarin
Vagifem
Estrace
Estring
Femring

Segment by Application, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
Vaginal Gels
Creams
Tablets
Rings
Patches

Regional and Country-level Analysis
The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Postmenopausal Vaginal Atrophy Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis
Postmenopausal Vaginal Atrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Postmenopausal Vaginal Atrophy Drugs business, the date to enter into the Postmenopausal Vaginal Atrophy Drugs market, Postmenopausal Vaginal Atrophy Drugs product introduction, recent developments, etc.
The major vendors covered:
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.


1 Study Coverage

  • 1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
    • 1.4.2 Premarin
    • 1.4.3 Vagifem
    • 1.4.4 Estrace
    • 1.4.5 Estring
    • 1.4.6 Femring
  • 1.5 Market by Application
    • 1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
    • 1.5.2 Vaginal Gels
    • 1.5.3 Creams
    • 1.5.4 Tablets
    • 1.5.5 Rings
    • 1.5.6 Patches
  • 1.6 Coronavirus Disease 2019 (Covid-19): Postmenopausal Vaginal Atrophy Drugs Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Postmenopausal Vaginal Atrophy Drugs Industry
      • 1.6.1.1 Postmenopausal Vaginal Atrophy Drugs Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Postmenopausal Vaginal Atrophy Drugs Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Executive Summary

  • 2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
    • 2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
    • 2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
  • 2.2 Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2020 Versus 2026
    • 2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Players

  • 3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
    • 3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
    • 3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
    • 3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
    • 3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
    • 3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
  • 3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
    • 3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
    • 3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
    • 4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
    • 4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
    • 4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
    • 4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

  • 5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
    • 5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
    • 5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
    • 5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
  • 5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Postmenopausal Vaginal Atrophy Drugs by Country
    • 6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
    • 6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
  • 6.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
    • 7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
    • 7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
  • 7.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Region
    • 8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
    • 8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
  • 8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
    • 9.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
    • 9.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
  • 9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
    • 10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
    • 10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
  • 10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Actavis plc
    • 11.1.1 Actavis plc Corporation Information
    • 11.1.2 Actavis plc Description, Business Overview and Total Revenue
    • 11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.1.5 Actavis plc Recent Development
  • 11.2 Bionovo, Inc.
    • 11.2.1 Bionovo, Inc. Corporation Information
    • 11.2.2 Bionovo, Inc. Description, Business Overview and Total Revenue
    • 11.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.2.5 Bionovo, Inc. Recent Development
  • 11.3 Endoceutics, Inc.
    • 11.3.1 Endoceutics, Inc. Corporation Information
    • 11.3.2 Endoceutics, Inc. Description, Business Overview and Total Revenue
    • 11.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.3.5 Endoceutics, Inc. Recent Development
  • 11.4 Novo Nordisk A/S
    • 11.4.1 Novo Nordisk A/S Corporation Information
    • 11.4.2 Novo Nordisk A/S Description, Business Overview and Total Revenue
    • 11.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.4.5 Novo Nordisk A/S Recent Development
  • 11.5 Pfizer Inc.
    • 11.5.1 Pfizer Inc. Corporation Information
    • 11.5.2 Pfizer Inc. Description, Business Overview and Total Revenue
    • 11.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.5.5 Pfizer Inc. Recent Development
  • 11.6 Teva Pharmaceuticals Ltd.
    • 11.6.1 Teva Pharmaceuticals Ltd. Corporation Information
    • 11.6.2 Teva Pharmaceuticals Ltd. Description, Business Overview and Total Revenue
    • 11.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.6.5 Teva Pharmaceuticals Ltd. Recent Development
  • 11.7 Therapeutics MD, Inc.
    • 11.7.1 Therapeutics MD, Inc. Corporation Information
    • 11.7.2 Therapeutics MD, Inc. Description, Business Overview and Total Revenue
    • 11.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.7.5 Therapeutics MD, Inc. Recent Development
  • 11.8 Shionogi & Company
    • 11.8.1 Shionogi & Company Corporation Information
    • 11.8.2 Shionogi & Company Description, Business Overview and Total Revenue
    • 11.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.8.5 Shionogi & Company Recent Development
  • 11.9 Allergan plc
    • 11.9.1 Allergan plc Corporation Information
    • 11.9.2 Allergan plc Description, Business Overview and Total Revenue
    • 11.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.9.5 Allergan plc Recent Development
  • 11.10 Shionogi & Co. Ltd.
    • 11.10.1 Shionogi & Co. Ltd. Corporation Information
    • 11.10.2 Shionogi & Co. Ltd. Description, Business Overview and Total Revenue
    • 11.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.10.5 Shionogi & Co. Ltd. Recent Development
  • 11.1 Actavis plc
    • 11.1.1 Actavis plc Corporation Information
    • 11.1.2 Actavis plc Description, Business Overview and Total Revenue
    • 11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
    • 11.1.5 Actavis plc Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
    • 12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2021-2026
  • 12.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
    • 12.2.1 North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
    • 12.2.2 North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
    • 12.2.3 North America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
    • 12.3.2 Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Postmenopausal Vaginal Atrophy Drugs Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source

    Summary:
    Get latest Market Research Reports on COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs. Industry analysis & Market Report on COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs is a syndicated market report, published as COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,900.00
    		$5,850.00
    		$7,800.00
    		3,014.70
    		4,522.05
    		6,029.40
    		3,630.90
    		5,446.35
    		7,261.80
    		595,491.00
    		893,236.50
    		1,190,982.00
    		329,160.00
    		493,740.00
    		658,320.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo